Literature DB >> 33990769

mTOR kinase activity disrupts a phosphorylation signaling network in schizophrenia brain.

Radhika Chadha1, Khaled Alganem2, Robert E Mccullumsmith2,3, James H Meador-Woodruff4.   

Abstract

The AKT-mTOR signaling transduction pathway plays an important role in neurodevelopment and synaptic plasticity. mTOR is a serine/threonine kinase that modulates signals from multiple neurotransmitters and phosphorylates specific proteins to regulate protein synthesis and cytoskeletal organization. There is substantial evidence demonstrating abnormalities in AKT expression and activity in different schizophrenia (SZ) models. However, direct evidence for dysregulated mTOR kinase activity and its consequences on downstream effector proteins in SZ pathophysiology is lacking. Recently, we reported reduced phosphorylation of mTOR at an activating site and abnormal mTOR complex formation in the SZ dorsolateral prefrontal cortex (DLPFC). Here, we expand on our hypothesis of disrupted mTOR signaling in the SZ brain and studied the expression and activity of downstream effector proteins of mTOR complexes and the kinase activity profiles of SZ subjects. We found that S6RP phosphorylation, downstream of mTOR complex I, is reduced, whereas PKCα phosphorylation, downstream of mTOR complex II, is increased in SZ DLPFC. In rats chronically treated with haloperidol, we showed that S6RP phosphorylation is increased in the rat frontal cortex, suggesting a potential novel mechanism of action for antipsychotics. We also demonstrated key differences in kinase signaling networks between SZ and comparison subjects for both males and females using kinome peptide arrays. We further investigated the role of mTOR kinase activity by inhibiting it with rapamycin in postmortem tissue and compared the impact of mTOR inhibition in SZ and comparison subjects using kinome arrays. We found that SZ subjects are globally more sensitive to rapamycin treatment and AMP-activated protein kinase (AMPK) contributes to this differential kinase activity. Together, our findings provide new insights into the role of mTOR as a master regulator of kinase activity in SZ and suggest potential targets for therapeutic intervention.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33990769     DOI: 10.1038/s41380-021-01135-9

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   13.437


  47 in total

1.  Altered serine/threonine kinase activity in schizophrenia.

Authors:  Jennifer L McGuire; John H Hammond; Stefani D Yates; Dongquan Chen; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Brain Res       Date:  2014-04-26       Impact factor: 3.252

2.  Abnormal activity of the MAPK- and cAMP-associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia.

Authors:  Adam J Funk; Robert E McCullumsmith; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2011-11-02       Impact factor: 7.853

3.  Mitogen-activated protein kinases in schizophrenia.

Authors:  S V Kyosseva; A D Elbein; W S Griffin; R E Mrak; M Lyon; C N Karson
Journal:  Biol Psychiatry       Date:  1999-09-01       Impact factor: 13.382

4.  Reduced GSK-3beta mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients.

Authors:  N Kozlovsky; C Shanon-Weickert; E Tomaskovic-Crook; J E Kleinman; R H Belmaker; G Agam
Journal:  J Neural Transm (Vienna)       Date:  2004-06-30       Impact factor: 3.575

5.  Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia.

Authors:  Effat S Emamian; Diana Hall; Morris J Birnbaum; Maria Karayiorgou; Joseph A Gogos
Journal:  Nat Genet       Date:  2004-01-25       Impact factor: 38.330

Review 6.  mTOR complexes in neurodevelopmental and neuropsychiatric disorders.

Authors:  Mauro Costa-Mattioli; Lisa M Monteggia
Journal:  Nat Neurosci       Date:  2013-10-28       Impact factor: 24.884

7.  AKT/GSK3 signaling pathway and schizophrenia.

Authors:  Effat S Emamian
Journal:  Front Mol Neurosci       Date:  2012-03-15       Impact factor: 5.639

Review 8.  Brain Development and Akt Signaling: the Crossroads of Signaling Pathway and Neurodevelopmental Diseases.

Authors:  Long Wang; Kai Zhou; Zhi Fu; Di Yu; Hesuyuan Huang; Xiaodong Zang; Xuming Mo
Journal:  J Mol Neurosci       Date:  2016-12-26       Impact factor: 3.444

Review 9.  Schizophrenia.

Authors:  Michael J Owen; Akira Sawa; Preben B Mortensen
Journal:  Lancet       Date:  2016-01-15       Impact factor: 79.321

10.  Abnormalities of signal transduction networks in chronic schizophrenia.

Authors:  Jennifer L McGuire; Erica A Depasquale; Adam J Funk; Sinead M O'Donnovan; Kathryn Hasselfeld; Shruti Marwaha; John H Hammond; Vahram Hartounian; James H Meador-Woodruff; Jarek Meller; Robert E McCullumsmith
Journal:  NPJ Schizophr       Date:  2017-09-12
View more
  11 in total

1.  GSK3β and mTORC1 Represent 2 Distinct Signaling Markers in Peripheral Blood Mononuclear Cells of Drug-Naive, First Episode of Psychosis Patients.

Authors:  Petros Petrikis; Alexandra Polyzou; Kyriaki Premeti; Argyro Roumelioti; Andreas Karampas; Georgios Georgiou; Dionysios Grigoriadis; George Leondaritis
Journal:  Schizophr Bull       Date:  2022-09-01       Impact factor: 7.348

2.  Molecular Features Triggered by Antipsychotic Medication in Brain Cells.

Authors:  Lívia Ramos-da-Silva; André S L M Antunes
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 3.  Schizophrenia and psychedelic state: Dysconnection versus hyper-connection. A perspective on two different models of psychosis stemming from dysfunctional integration processes.

Authors:  Jacopo Sapienza; Marta Bosia; Marco Spangaro; Francesca Martini; Giulia Agostoni; Federica Cuoco; Federica Cocchi; Roberto Cavallaro
Journal:  Mol Psychiatry       Date:  2022-08-05       Impact factor: 13.437

Review 4.  The active kinome: The modern view of how active protein kinase networks fit in biological research.

Authors:  Khaled Alganem; Abdul-Rizaq Hamoud; Justin F Creeden; Nicholas D Henkel; Ali S Imami; Alex W Joyce; William G Ryan V; Jacob B Rethman; Rammohan Shukla; Sinead M O'Donovan; Jarek Meller; Robert McCullumsmith
Journal:  Curr Opin Pharmacol       Date:  2021-12-27       Impact factor: 4.768

5.  Exposure to the Amino Acids Histidine, Lysine, and Threonine Reduces mTOR Activity and Affects Neurodevelopment in a Human Cerebral Organoid Model.

Authors:  Amber Berdenis van Berlekom; Raphael Kübler; Jeske W Hoogeboom; Daniëlle Vonk; Jacqueline A Sluijs; R Jeroen Pasterkamp; Jinte Middeldorp; Aletta D Kraneveld; Johan Garssen; René S Kahn; Elly M Hol; Lot D de Witte; Marco P Boks
Journal:  Nutrients       Date:  2022-05-23       Impact factor: 6.706

6.  A Learning Based Framework for Disease Prediction from Images of Human-Derived Pluripotent Stem Cells of Schizophrenia Patients.

Authors:  Nickolas Fularczyk; Jessica Di Re; Laura Stertz; Consuelo Walss-Bass; Fernanda Laezza; Demetrio Labate
Journal:  Neuroinformatics       Date:  2022-01-22

Review 7.  Mechanistic/mammalian target of rapamycin and side effects of antipsychotics: insights into mechanisms and implications for therapy.

Authors:  Chuanjun Zhuo; Yong Xu; Weihong Hou; Jiayue Chen; Qianchen Li; Zhidong Liu; Guangqian Dou; Yun Sun; Ranli Li; Xiaoyan Ma; Hongjun Tian; Chunhua Zhou
Journal:  Transl Psychiatry       Date:  2022-01-10       Impact factor: 6.222

8.  KRSA: An R package and R Shiny web application for an end-to-end upstream kinase analysis of kinome array data.

Authors:  Erica A K DePasquale; Khaled Alganem; Eduard Bentea; Nawshaba Nawreen; Jennifer L McGuire; Tushar Tomar; Faris Naji; Riet Hilhorst; Jaroslaw Meller; Robert E McCullumsmith
Journal:  PLoS One       Date:  2021-12-17       Impact factor: 3.240

9.  Multi-omics integration and interactomics reveals molecular networks and regulators of the beneficial effect of yoga and exercise.

Authors:  Manoj Khokhar; Sojit Tomo; Ashita Gadwal; Purvi Purohit
Journal:  Int J Yoga       Date:  2022-03-21

10.  Identifying therapeutic targets for schizophrenia.

Authors:  Karli Montague-Cardoso
Journal:  Commun Biol       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.